Important Notice to Long-Term Shareholders of GRAIL, Inc. (NASDAQ: GRAL); New Era Energy & Digital, Inc. (NASDAQ: NUAI) (FKA New Era Helium (NASDAQ: NEHC)); Photronics, Inc. (NASDAQ: PLAB); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf

These investigations signal serious red flags and immediate risks for shareholders in all four companies.

What the company is saying

The companies named—GRAIL, Inc. (NASDAQ: GRAL), New Era Energy & Digital, Inc. (NASDAQ: NUAI), Photronics, Inc. (NASDAQ: PLAB), and Power Solutions International, Inc. (NASDAQ: PSIX)—are not directly communicating in this announcement; rather, the narrative is constructed by Grabar Law Office, which is soliciting shareholders for potential legal action. The core message is that each company is accused of misleading investors through false statements, omissions, or misrepresentations about critical business developments. For GRAIL, the focus is on the failed NHS-Galleri cancer screening trial, where management allegedly overstated the likelihood of success and highlighted interim positives while omitting key risks about the study’s design and timeline. New Era Energy & Digital is accused of misrepresenting progress on its Texas Critical Data Centers project and engaging in questionable related-party transactions, with the situation escalating to a lawsuit by the New Mexico Attorney General. Photronics is alleged to have misled investors about demand for its high-end IC photomask products, only for revenue and guidance to fall short, triggering a sharp stock price drop. Power Solutions International is accused of overstating its ability to capture data center market demand and downplaying the costs and challenges of manufacturing expansion. The announcement is blunt, legalistic, and accusatory, with no attempt at reassurance or positive spin. Notably, Everett Willard Gray II is identified as CEO of New Era Energy & Digital and is named in the Attorney General’s lawsuit, which heightens the seriousness of the allegations for that company. The overall communication style is adversarial and focused on mobilizing shareholder action, not on defending or contextualizing the companies’ positions.

What the data suggests

The disclosed numbers paint a starkly negative picture for all four companies. GRAIL’s stock price fell by more than 50% in a single trading day after announcing its NHS-Galleri trial failed to meet its primary endpoint—a statistically significant reduction in Stage III-IV cancers—on February 19, 2026. This collapse signals a catastrophic loss of investor confidence and a direct financial hit to shareholders. Photronics’ stock price dropped from $53.51 to $34.02 per share (a 36.4% decline) on May 28, 2026, after reporting revenue below expectations, an 11% sequential decline in IC revenue, and issuing third-quarter guidance below market expectations. These figures confirm that the company’s prior narrative of strong demand was not supported by actual results. For New Era Energy & Digital, the data point is the December 29, 2025, filing of a lawsuit by the New Mexico Attorney General, which is a material legal and reputational risk, though no financial figures are disclosed. Power Solutions International’s issues are described in qualitative terms, with no hard numbers, but the implication is that its sales pipeline and manufacturing claims were overstated. Across all cases, the gap between what was previously claimed and what has materialized is wide and damaging. There is no evidence that prior targets or guidance were met; in fact, the only concrete numbers are negative surprises. The financial disclosures are partial and event-driven, lacking comprehensive financial statements or operational metrics, which limits the ability to assess the full scope of the damage. An independent analyst would conclude that the immediate financial trajectory for these companies is sharply negative, with realized losses and ongoing legal exposure.

Analysis

The announcement is a factual summary of shareholder investigations and securities fraud complaints against four NASDAQ-listed companies, with a focus on alleged misstatements and recent negative events. The tone is negative, reflecting failed clinical trial endpoints, regulatory actions, and missed financial guidance, all of which are supported by realised events such as stock price declines and revenue shortfalls. There is minimal forward-looking language, and what exists (e.g., 'additional follow-up may be necessary') is cautious rather than promotional. No capital outlays or long-term benefit projections are discussed, and the announcement does not attempt to inflate the companies' prospects. The gap between narrative and evidence is negligible; the text is grounded in disclosed facts and legal actions, not aspirational claims. No hype or narrative inflation is present.

Risk flags

• ●Operational risk is acute for GRAIL, as the failure of the NHS-Galleri trial’s primary endpoint undermines the company’s core value proposition and future revenue potential. This is compounded by the lack of disclosed contingency plans or alternative growth drivers.
• ●Legal and regulatory risk is high for New Era Energy & Digital, which faces a lawsuit from the New Mexico Attorney General alleging a 'fraudulent oil-and-gas scheme.' The involvement of the CEO, Everett Willard Gray II, in the suit increases the likelihood of significant operational disruption and reputational damage.
• ●Disclosure risk is present across all companies, as the allegations center on material omissions and misleading statements. Investors are left without reliable information to assess true business performance, which increases the probability of further negative surprises.
• ●Financial risk is immediate and severe, as evidenced by the 50%+ and 36.4% single-day stock price declines for GRAIL and Photronics, respectively. These losses are realized, not theoretical, and suggest that market confidence has been badly shaken.
• ●Execution risk is high for Power Solutions International, which is accused of overstating its ability to capture data center market demand and underestimating the costs of manufacturing expansion. Without clear evidence of demand or cost control, future performance is highly uncertain.
• ●Pattern-based risk is evident in the repeated theme of companies allegedly overstating prospects and underdisclosing risks, which may indicate systemic governance or cultural issues that could persist beyond the current events.
• ●Timeline risk is minimal for the negative events, as they have already occurred, but any potential recovery or legal resolution is likely to be protracted and uncertain, making it difficult for investors to forecast when, if ever, value might be restored.
• ●Geographic and jurisdictional risk is present for New Era Energy & Digital, given the involvement of the New Mexico Attorney General and the mention of Mexico as a location, which could complicate legal proceedings and enforcement.

Bottom line

For investors, this announcement is a clear warning sign that all four companies—GRAIL, New Era Energy & Digital, Photronics, and Power Solutions International—are facing immediate and material threats to shareholder value. The allegations are not abstract or distant; they are tied to realized events such as failed clinical trials, missed revenue targets, and active regulatory lawsuits, all of which have already triggered sharp declines in stock prices. The credibility of management at these companies is in serious question, as the only hard data disclosed are negative surprises and legal actions, with no evidence of mitigating factors or credible turnaround plans. The involvement of a named CEO (Everett Willard Gray II) in a state-level fraud lawsuit is particularly damaging for New Era Energy & Digital, but none of the companies escape unscathed. To change this assessment, the companies would need to provide transparent, detailed financial disclosures, credible explanations for the alleged misstatements, and evidence of operational or legal progress. Investors should closely monitor for updates on legal proceedings, restatements of financials, and any signs of management change or governance reform. At present, the signal is not actionable for new investment—these are stocks to avoid or exit, not to buy on weakness. The most important takeaway is that the risks are real, immediate, and grounded in hard events, not just allegations; investors should not expect a quick or easy recovery.

Announcement summary

(NASDAQ: GRAL) Grabar Law Office is investigating claims on behalf of shareholders of GRAIL, Inc. (NASDAQ: GRAL) regarding alleged breaches of fiduciary duty and securities fraud related to the NHS-Galleri cancer screening trial, which failed to achieve its primary endpoint of a statistically significant reduction in Stage III-IV cancers as announced on February 19, 2026. The complaint alleges that GRAIL, Inc. made false and/or misleading statements about the likelihood of the trial's success and highlighted positive interim metrics while omitting material information about the study's design and follow-up period. Following the announcement, GRAIL's stock price fell more than 50% in a single trading day. (NASDAQ: NUAI) Grabar Law Office is also investigating New Era Energy & Digital, Inc. (NASDAQ: NUAI), formerly New Era Helium (NASDAQ: NEHC), for alleged false and misleading statements regarding its Texas Critical Data Centers project, permitting progress, and related-party oil and gas transactions, with a federal lawsuit filed by the New Mexico Attorney General on December 29, 2025. (NASDAQ: PLAB) Photronics, Inc. (NASDAQ: PLAB) is under investigation for allegedly making materially false or misleading statements about demand for its high-end IC photomask products, with its stock price dropping from $53.51 to $34.02 per share (a 36.4% decline) on May 28, 2026, after reporting revenue below expectations and an 11% sequential decline in IC revenue. (NASDAQ: PSIX) Power Solutions International, Inc. (NASDAQ: PSIX) is being investigated for allegedly overstating its ability to capture sales demand in the data center market and understating the impact and costs of manufacturing capacity enhancements. The company projects that additional follow-up may be necessary to adequately assess the NHS-Galleri trial's effectiveness. Investors in all four companies are encouraged to seek corporate reforms, the return of funds, and court-approved incentive awards at no cost.

Disagree with this article?